FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000217639> ?p ?o ?g. }

• W2000217639 endingPage "B189" @default.
• W2000217639 startingPage "B189" @default.
• W2000217639 abstract "Abstract Endometrial cancers are the most common gynecologic cancers in the US, and are a heterogeneous group of malignancies with distinct molecular characteristics. The phosphatidylinositol-3-kinase (PI3K)-AKT-mammalian target of rapamycin (mTOR) pathway is frequently dysregulated, being activated in 70-80% of hormone-dependent endometrioid carcinomas (Type I) and 40% of non-endometrioid carcinomas (Type II). Loss of PTEN or activation of PIK3CA results in constitutive activation of AKT and up-regulation of mTOR. We evaluated MLN0128, an investigational catalytic mTORC1/2 inhibitor, in preclinical models of endometrial cancer to assess its activity as a single agent and in combination with paclitaxel across various dose schedules and sequences. In vitro MLN0128 showed antiproliferative activity with IC50 values of 5-100 nM across cell line models (n=9) with various genetic aberrations including complex combinations of PTEN loss and mutations in PIK3CA, KRAS and/or FGFR. This antiproliferative activity was associated with inhibition of pathway markers, including phosphorylated AKT, S6, and 4EBP1. In vivo MLN0128 demonstrated tumor growth inhibition (TGI) in a PIK3CA/KRAS model (HEC-1A) and a PTEN/FGFR model (AN3CA) with TGI values of 62% and 73%, respectively. Similar TGI values were achieved regardless of dosing schedule (once daily [QD], 3 days a week [QDx3D], or once weekly [QW]). TGI could be improved by using a combination approach. In the AN3CA model, the in vitro combination of MLN0128 and paclitaxel suppressed the PI3K pathway activation (phosphorylation of AKT, S6, and 4EBP1) that occurred when paclitaxel was administered alone; the combination also suppressed S6 phosphorylation at 24 hours. This finding correlated with an increase in the induction of cleaved PARP, a marker of apoptosis, and accumulation of cells in the sub-G1 phase of the cell cycle. The combination was also observed to add benefit in vivo, most prominently when tumor regrowth was assessed. In the HEC-1A model, TGI only increased by 10% with concomitant administration of MLN0128 and paclitaxel daily vs MLN0128 alone. However, when monitoring re-growth 18 days after administration, this difference in TGI (combination vs MLN0128 alone) increased to 44%. Furthermore pretreatment with paclitaxel before MLN0128 was also associated with significant enhancement of antitumor activity relative to the concomitant administration of both agents; this effect was observed with the QDx3D and QW MLN0128 schedules. Results from these preclinical studies support further investigation of MLN0128 in endometrial cancer, either as a single agent or in combination with current standards of care. Phase 1 studies are ongoing to investigate single-agent MLN0128 (NCT01058707) and MLN0128 plus paclitaxel (NCT01351350) in advanced solid tumors. Citation Information: Mol Cancer Ther 2013;12(11 Suppl):B189. Citation Format: Karuppiah Kannan, Robyn Fabrey, Jodi Cooper, Jessica Huck, Esha Gangolli, Eric Westin, Rachael Brake. MLN0128, an investigational mTORC1/2 inhibitor, demonstrates potent antitumor activity alone and in combination with paclitaxel in preclinical models of endometrial cancer. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 Oct 19-23; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2013;12(11 Suppl):Abstract nr B189." @default.
• W2000217639 created "2016-06-24" @default.
• W2000217639 creator A5008844588 @default.
• W2000217639 creator A5009944397 @default.
• W2000217639 creator A5032147604 @default.
• W2000217639 creator A5032489851 @default.
• W2000217639 creator A5047257123 @default.
• W2000217639 creator A5058656724 @default.
• W2000217639 creator A5085125820 @default.
• W2000217639 date "2013-11-01" @default.
• W2000217639 modified "2023-09-26" @default.
• W2000217639 title "Abstract B189: MLN0128, an investigational mTORC1/2 inhibitor, demonstrates potent antitumor activity alone and in combination with paclitaxel in preclinical models of endometrial cancer." @default.
• W2000217639 doi "https://doi.org/10.1158/1535-7163.targ-13-b189" @default.
• W2000217639 hasPublicationYear "2013" @default.
• W2000217639 type Work @default.
• W2000217639 sameAs 2000217639 @default.
• W2000217639 citedByCount "2" @default.
• W2000217639 countsByYear W20002176392017 @default.
• W2000217639 countsByYear W20002176392023 @default.
• W2000217639 crossrefType "journal-article" @default.
• W2000217639 hasAuthorship W2000217639A5008844588 @default.
• W2000217639 hasAuthorship W2000217639A5009944397 @default.
• W2000217639 hasAuthorship W2000217639A5032147604 @default.
• W2000217639 hasAuthorship W2000217639A5032489851 @default.
• W2000217639 hasAuthorship W2000217639A5047257123 @default.
• W2000217639 hasAuthorship W2000217639A5058656724 @default.
• W2000217639 hasAuthorship W2000217639A5085125820 @default.
• W2000217639 hasConcept C11960822 @default.
• W2000217639 hasConcept C121608353 @default.
• W2000217639 hasConcept C126322002 @default.
• W2000217639 hasConcept C185592680 @default.
• W2000217639 hasConcept C2776999253 @default.
• W2000217639 hasConcept C2777088508 @default.
• W2000217639 hasConcept C2777292972 @default.
• W2000217639 hasConcept C2777609662 @default.
• W2000217639 hasConcept C2781187634 @default.
• W2000217639 hasConcept C502942594 @default.
• W2000217639 hasConcept C526805850 @default.
• W2000217639 hasConcept C55493867 @default.
• W2000217639 hasConcept C62478195 @default.
• W2000217639 hasConcept C71924100 @default.
• W2000217639 hasConcept C75217442 @default.
• W2000217639 hasConcept C86554907 @default.
• W2000217639 hasConcept C98274493 @default.
• W2000217639 hasConcept C98490376 @default.
• W2000217639 hasConceptScore W2000217639C11960822 @default.
• W2000217639 hasConceptScore W2000217639C121608353 @default.
• W2000217639 hasConceptScore W2000217639C126322002 @default.
• W2000217639 hasConceptScore W2000217639C185592680 @default.
• W2000217639 hasConceptScore W2000217639C2776999253 @default.
• W2000217639 hasConceptScore W2000217639C2777088508 @default.
• W2000217639 hasConceptScore W2000217639C2777292972 @default.
• W2000217639 hasConceptScore W2000217639C2777609662 @default.
• W2000217639 hasConceptScore W2000217639C2781187634 @default.
• W2000217639 hasConceptScore W2000217639C502942594 @default.
• W2000217639 hasConceptScore W2000217639C526805850 @default.
• W2000217639 hasConceptScore W2000217639C55493867 @default.
• W2000217639 hasConceptScore W2000217639C62478195 @default.
• W2000217639 hasConceptScore W2000217639C71924100 @default.
• W2000217639 hasConceptScore W2000217639C75217442 @default.
• W2000217639 hasConceptScore W2000217639C86554907 @default.
• W2000217639 hasConceptScore W2000217639C98274493 @default.
• W2000217639 hasConceptScore W2000217639C98490376 @default.
• W2000217639 hasIssue "11_Supplement" @default.
• W2000217639 hasLocation W20002176391 @default.
• W2000217639 hasOpenAccess W2000217639 @default.
• W2000217639 hasPrimaryLocation W20002176391 @default.
• W2000217639 hasRelatedWork W1607074945 @default.
• W2000217639 hasRelatedWork W2022014232 @default.
• W2000217639 hasRelatedWork W2064116264 @default.
• W2000217639 hasRelatedWork W2066012740 @default.
• W2000217639 hasRelatedWork W2165450197 @default.
• W2000217639 hasRelatedWork W2180010206 @default.
• W2000217639 hasRelatedWork W2566402427 @default.
• W2000217639 hasRelatedWork W2614355659 @default.
• W2000217639 hasRelatedWork W2789877319 @default.
• W2000217639 hasRelatedWork W2912656088 @default.
• W2000217639 hasVolume "12" @default.
• W2000217639 isParatext "false" @default.
• W2000217639 isRetracted "false" @default.
• W2000217639 magId "2000217639" @default.
• W2000217639 workType "article" @default.